MD On-Line streamlines transactions for Blue Shield of California
SAN FRANCISCO and PARSIPPANY, N.J. MD On-Line is teaming up with Blue Shield of California to offer providers a free online service for submitting health care claims and other health care transactions. The goal of the new service is to make it easier for physicians and other medical providers to do business with Blue Shield by streamlining transaction processes, generating faster payment and error correction, and speeding up revenue cycles.
The free, easy-to-use claims portal does not require a contract or software to install – providers need only contact MD On-Line to enroll and start using the service.
“Working with MD On-Line allows us to offer providers another easy and straightforward way to submit claims to Blue Shield,” said Bob Novelli, executive vice president of customer services and corporate marketing at Blue Shield of California. “We are committed to making health coverage easier for Californians, and this new venture with MD On-Line ensures a seamless claims process for providers.”
Eli Lilly introduces its third new insulin pen in the past year
INDIANAPOLIS Eli Lilly today launched its new insulin pen, KwikPen, which is prefilled with the Humalog brand of insulins. This is the third new insulin pen launched by the company in the last 12 months, following the launches of HumaPen MEMOIR, a digital insulin pen and HumaPen LUXURA, a reusable pen for people who need insulin dosing in smaller increments.
KwikPen is now available by prescription in pharmacies prefilled with the Humalog brand of insulins, including Humalog, Humalog Mix75/25 and Humalog Mix50/50. Patients using the original Humalog and Humalog Mixtures prefilled pen do not need to convert at this time.
“KwikPen, prefilled with Humalog and Humalog Mixtures, provides people with diabetes an exciting new option for accurate insulin dosing with the convenience of an easy-to-use prefilled pen,” said Matt Beebe, Humalog brand leader, Lilly USA.
Pfizer to acquire Encysive, will gain rights to Thelin
NEW YORK Pfizer has announced that it intends on buying Encysive Pharmaceuticals for about $195 million, according to the Associated Press.
As part of the deal, Pfizer would gain the rights to Encysive’s drug Thelin, which is approved in some European countries for the treatment of high blood pressure in the pulmonary artery. The drug is still awaiting approval in the U.S. Pfizer would also gain access to the rest of Encysive’s portfolio of drugs.
Pfizer already markets Revatio for high blood pressure in the pulmonary artery and Thelin would only strengthen the market for the company. Pfizer plans on conducting a late-stage trial of Thelin in the U.S. in hopes of obtaining final approval from the Food and Drug Administration.
Analysts project the drug could make about $100 million annually by 2012.